Pfizer Inc. $PFE is QSM Asset Management Ltd’s 2nd Largest Position

QSM Asset Management Ltd lifted its stake in shares of Pfizer Inc. (NYSE:PFE) by 13.8% during the second quarter, HoldingsChannel.com reports. The firm owned 559,438 shares of the biopharmaceutical company’s stock after purchasing an additional 67,800 shares during the quarter. Pfizer makes up 7.0% of QSM Asset Management Ltd’s portfolio, making the stock its 2nd largest position. QSM Asset Management Ltd’s holdings in Pfizer were worth $13,471,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the stock. Godfrey Financial Associates Inc. purchased a new position in Pfizer during the 4th quarter valued at about $26,000. Keb Asset Management LLC purchased a new stake in shares of Pfizer in the second quarter worth about $26,000. HFM Investment Advisors LLC boosted its position in shares of Pfizer by 61.0% in the fourth quarter. HFM Investment Advisors LLC now owns 1,127 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 427 shares during the period. Evolution Wealth Management Inc. grew its stake in Pfizer by 132.2% during the first quarter. Evolution Wealth Management Inc. now owns 994 shares of the biopharmaceutical company’s stock valued at $28,000 after acquiring an additional 566 shares in the last quarter. Finally, Abound Financial LLC purchased a new position in Pfizer during the fourth quarter valued at approximately $31,000. Institutional investors own 68.36% of the company’s stock.

Analysts Set New Price Targets

Several analysts have issued reports on PFE shares. HSBC cut shares of Pfizer from a “buy” rating to a “hold” rating and lowered their target price for the stock from $32.00 to $28.00 in a research note on Monday, July 6th. Weiss Ratings restated a “hold (c)” rating on shares of Pfizer in a research report on Monday, August 3rd. Royal Bank Of Canada upgraded Pfizer from an “underperform” rating to a “sector perform” rating and set a $25.00 price objective on the stock in a research report on Tuesday, June 9th. UBS Group reissued a “neutral” rating and set a $27.00 price objective on shares of Pfizer in a research note on Wednesday, May 27th. Finally, JPMorgan Chase & Co. reduced their target price on Pfizer from $30.00 to $28.00 and set a “neutral” rating for the company in a research report on Wednesday, July 8th. One research analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating, fourteen have given a Hold rating and two have issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Pfizer has an average rating of “Hold” and a consensus price target of $28.28.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: CEO Albert Bourla purchased approximately $1 million of Pfizer stock—about 38,000 shares—in his first open-market purchase of the company’s shares. The transaction may reassure investors that management views the current valuation as attractive. Pfizer CEO Buys $1 Million of Company Stock
• Positive Sentiment: The European Medicines Agency validated Pfizer and Valneva’s application for their six-valent Lyme disease vaccine candidate, PF-07307405, beginning the formal review process. The filing is supported by Phase 3 results showing more than 70% efficacy and no significant safety concerns. Validation is an important regulatory milestone, although it does not represent approval. Pfizer and Valneva’s Lyme Disease Vaccine Candidate Marketing Authorization Application Validated by European Medicines Agency
• Positive Sentiment: An updated Korean real-world study of Paxlovid highlighted continued potential value for high-risk COVID-19 patients, supporting Pfizer’s effort to maintain demand for its antiviral as COVID-related revenue normalizes. Pfizer’s Korean Paxlovid Study Signals Ongoing Value in High-Risk COVID Market
• Neutral Sentiment: Erste Group Bank raised its fiscal 2026 EPS forecast, adding modest analyst support. Pfizer’s broader investment case also continues to rely on its non-COVID portfolio, including positive Phase 3 LITFULO data and recently acquired products.
• Negative Sentiment: Investors remain focused on Pfizer’s post-COVID revenue declines, recent intangible-asset impairments, and the discontinuation of its BEQVEZ hemophilia gene therapy, which underscore execution and pipeline risks. Gene Therapy Remains Top-of-Mind in Hemophilia

Pfizer Stock Down 0.1%

PFE opened at $26.77 on Friday. The business’s fifty day simple moving average is $25.12 and its 200 day simple moving average is $26.20. Pfizer Inc. has a 52 week low of $23.58 and a 52 week high of $28.75. The company has a quick ratio of 0.96, a current ratio of 1.27 and a debt-to-equity ratio of 0.71. The stock has a market cap of $152.60 billion, a PE ratio of 35.23 and a beta of 0.34.

Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 4th. The biopharmaceutical company reported $0.77 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.68 by $0.09. The firm had revenue of $15.03 billion during the quarter, compared to analyst estimates of $14.40 billion. Pfizer had a return on equity of 19.63% and a net margin of 6.80%.The company’s revenue was up 2.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.78 earnings per share. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. As a group, research analysts expect that Pfizer Inc. will post 2.98 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, September 1st. Investors of record on Friday, July 24th will be given a $0.43 dividend. The ex-dividend date is Friday, July 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.4%. Pfizer’s payout ratio is presently 226.32%.

About Pfizer

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.